Drug Shortage Report for LEVOTHYROXINE SODIUM INJECTION
Report ID | 173469 |
Drug Identification Number | 02499916 |
Brand name | LEVOTHYROXINE SODIUM INJECTION |
Common or Proper name | LEVOTHYROXINE SODIUM INJECTION |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | LEVOTHYROXINE SODIUM |
Strength(s) | 40MCG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAMUSCULAR |
Packaging size | 5 mL |
ATC code | H03AA |
ATC description | THYROID PREPARATIONS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2022-12-31 |
Actual start date | 2022-12-31 |
Estimated end date | 2023-03-08 |
Actual end date | 2023-03-08 |
Shortage status | Resolved |
Updated date | 2023-03-10 |
Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Levothyroxine Sodium Injection 40 mcg/mL SD Vial 5 mL and 100 mcg/mL SD Vial 5 mL effective December 31, 2022 until March 8, 2023. Please note all current inventory of these products is currently short-dated and expires December 31, 2022. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v7 | 2023-03-10 | French | Compare |
v6 | 2023-03-10 | English | Compare |
v5 | 2023-02-15 | French | Compare |
v4 | 2023-02-15 | English | Compare |
v3 | 2023-01-01 | English | Compare |
v2 | 2022-11-03 | French | Compare |
v1 | 2022-11-03 | English | Compare |
Showing 1 to 7 of 7